NCT04019002View on ClinicalTrials.gov

Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 19, 2019

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Glioblastoma Multiforme (GBM)

Interventions

DRUG

Hyperpolarized 13C Pyruvate

Given at 0.43 milliliters/kilogram body weight of a 250 millimolar (mM) solution via intravenous injection over a period of about 1 minute once prior to each research magnetic resonance imaging procedure.

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Susan Chang

OTHER

NCT04019002 - Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma | Biotech Hunter | Biotech Hunter